Boston Scientific Corporation (NYSE:BSX) EVP Joseph Michael Fitzgerald sold 85,227 shares of the business’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $26.48, for a total value of $2,256,810.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Shares of Boston Scientific Corporation (NYSE:BSX) traded up $0.22 during midday trading on Friday, reaching $25.42. The company’s stock had a trading volume of 1,268,451 shares, compared to its average volume of 9,674,697. Boston Scientific Corporation has a 12-month low of $23.29 and a 12-month high of $29.93. The firm has a market capitalization of $34,600.00, a PE ratio of 363.14, a P/E/G ratio of 1.91 and a beta of 0.81. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.72 and a quick ratio of 0.50.
Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Thursday, February 1st. The medical equipment provider reported $0.34 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.34. Boston Scientific had a return on equity of 24.04% and a net margin of 1.15%. The business had revenue of $2.41 billion during the quarter, compared to analyst estimates of $2.39 billion. During the same period in the prior year, the company posted $0.30 EPS. The business’s revenue for the quarter was up 9.9% compared to the same quarter last year. research analysts anticipate that Boston Scientific Corporation will post 1.37 EPS for the current fiscal year.
Hedge funds and other institutional investors have recently modified their holdings of the business. Valeo Financial Advisors LLC bought a new position in Boston Scientific during the 3rd quarter valued at $138,000. Steward Partners Investment Advisory LLC acquired a new stake in shares of Boston Scientific in the third quarter valued at about $139,000. Cerebellum GP LLC acquired a new stake in shares of Boston Scientific in the fourth quarter valued at about $126,000. Ironwood Investment Counsel LLC acquired a new stake in shares of Boston Scientific in the third quarter valued at about $204,000. Finally, Perkins Capital Management Inc. acquired a new stake in shares of Boston Scientific in the third quarter valued at about $204,000. 90.15% of the stock is owned by hedge funds and other institutional investors.
Boston Scientific Company Profile
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.